Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 5
Clinical study of ctDNA-based MRD detection and INTERCEPT program update
The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).
EP: 1.Overview of colorectal cancer and its management
EP: 2.Background on Colorectal Cancer Screening and its Role in Patient Care
EP: 3.Circulating Tumor DNA Detection Techniques
EP: 4.Describing the Value of ctDNA in Clinical Practice
Now Viewing
EP: 5.Clinical study of ctDNA-based MRD detection and INTERCEPT program update
EP: 6.Recent findings from BESPOKE
EP: 7.Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
EP: 8.Key Considerations for Selection of ctDNA Detection Methods
EP: 9.Clinical Utility of ctDNA Testing
EP: 10.Barriers to Implementing ctDNA Testing
EP: 11.ctDNA Testing in a CRC Clinical Scenario
EP: 12.ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
EP: 13.Interpreting and Communicating ctDNA Results
EP: 14.Addressing Gaps in ctDNA Testing
EP: 15.Exploring the Future of ctDNA and Novel Treatment Strategies
- Please describe some recent studies exploring the utility of ctDNA in CRC
- Dr Dasari: INTERCEPT program: ctDNA testing for MRD in CRC
- Association of positive ctDNA-based MRD assays during surveillance and undiagnosed concomitant radiographic recurrences CRC (Dasari, et al. ASCO 2023. Abstract 3522.)
- Results from a prospective real-world clinical cohort (Maddalena, et al. ASCO GI 2024. Abstract 27.)
Recent Videos
Related Content
